With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
5317-33-9, Di- tert-butyl azodicarboxylate (0.478 g, 2.08 mmol) was added portionwise to a mixture of 4-chloro-7-hydroxy-6-methoxyquinazoline (0.350 g, 1.66 mmol), 3-(4-methyl-piperazin-1-yl)-propan-1-ol (Intermediate 7, 0.276 g, 1.74mmol), and triphenylphosphine (0.544 g, 2.08 mmol) in dichloromethane (20 mL) at r.t.. If necessary, further alcoholwas added. After stirring for 2 h, the solution was concentrated to 10 mL, mounted on silica and chromatographed(gradient, dichloromethane to dichloromethane : methanol = 3:2 within 1 h) to obtain 4-chloro-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline (brownish solid, 0.431 g, 1.23 mmol, 74 %). LC/ESI-MS: m/ z = 351 [M(35Cl) +H]+;Rt = 1.88 min. Cf. also WO 04/043472, page 32.
5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.
Reference：
Patent; 4SC AG; EP1674467; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics